Back to search results

A Study Comparing JNJ-79635322 and Teclistamab for Multiple Myeloma

This study is comparing two treatments, JNJ-79635322 and Teclistamab, for people with relapsed or refractory multiple myeloma (a type of blood cancer that has come back or not responded to previous treatments). Both drugs are given as an injection under the skin. The study aims to see how well each drug works by measuring if your cancer goes away completely (Complete Response) or if it takes longer for your cancer to get worse (Progression-Free Survival) over about 41 months. You might be able to join if you are 18 or older, have measurable multiple myeloma, and have already received 1 to 3 prior treatments, including an anti-CD38 antibody. The current status of this study is unclear.

Study design
This interventional study plans to enroll 700 participants to compare JNJ-79635322 and Teclistamab.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for up to approximately 41 months to assess treatment outcomes.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07518186

A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

Recruiting
PHASE3Ages 18+InterventionalTreatment
Janssen Research & Development, LLC
~700 participants
Updated 2026-08-28 on ClinicalTrials.gov
What's tested:JNJ-79635322Teclistamab

At a glance

Recruiting sites
151 of 151 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Complete Response (CR) or Better
Measured over Up to approximately 41 months
+1 more outcome measured

Conditions

Multiple Myeloma

Explore related trials

Multiple Myeloma

Where it's being run

151 sites across 39 states
China12
Spain11
Japan10
Turkey (Türkiye)10
Italy9
Brazil8
India7
South Korea7

Study leadership

  • Janssen Research & Development, LLC Clinical Trial · STUDY_DIRECTOR · Janssen Research & Development, LLC

Who to contact

Study Contact
[email protected]
844-434-4210
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Documented diagnosis of multiple myeloma (MM) as defined by the criteria below: a. MM diagnosis according to the international myeloma working group (IMWG) diagnostic criteria, b. Measurable disease at screening as assessed by central laboratory
Received 1 to 3 prior lines of antimyeloma therapy, including an anti-cluster of differentiation (CD) 38 antibody and lenalidomide
Have an eastern cooperative oncology group (ECOG) performance status of 0 to 2 at screening and immediately before the first dose of study medication
Have clinical laboratory values meeting the criteria specified in the protocol during the screening and within 1 day of the start of administration of study treatment

Exclusion

Major surgery, (for example, requiring general anesthesia) or significant traumatic injury within 2 weeks prior to first dose, or will not have fully recovered from surgery, or has surgery planned during the time the participant is expected to participate in the study
Suspected or known allergies, hypersensitivity, intolerance or other contraindications to the use of JNJ-79635322 or teclistamab or their excipients
Presence of any of the following: i. Any ongoing myelodysplastic syndrome or B-cell malignancy (other than MM); ii. Any history of malignancy, other than MM, that is considered at high risk of recurrence requiring systemic therapy; iii. Any active malignancy (that is, progressing or requiring treatment change in the last 24 months) other than MM
Known active or prior central nervous system (CNS) involvement or exhibits clinical signs of meningeal involvement of MM. If either is suspected, negative whole brain magnetic resonance imaging (MRI) and lumbar cytology are required

What this trial measures

  • Complete Response (CR) or BetterUp to approximately 41 months

    CR or better is defined as the percentage of participants achieving CR or stringent complete response (sCR) prior to subsequent antimyeloma therapy in accordance with the international myeloma working group (IMWG) criteria during or after the study treatment.

  • Progression-Free Survival (PFS)Up to approximately 41 months

    PFS is defined as the duration from the date of randomization to either progressive disease (PD) or death, whichever comes first. Disease progression will be determined according to the IMWG response criteria.